@article{
 title = {A pivot from synaptic monoamine processes to further downstream processes: The impact of ketamine research},
 type = {article},
 year = {2018},
 identifiers = {[object Object]},
 pages = {1-4},
 websites = {http://doi.wiley.com/10.1111/ppc.12317},
 month = {7},
 publisher = {Wiley/Blackwell (10.1111)},
 day = {24},
 id = {17a97430-5709-35dd-b71d-1df9c0f10500},
 created = {2018-11-07T20:29:07.373Z},
 accessed = {2018-07-29},
 file_attached = {false},
 profile_id = {078d13e5-632a-3ebf-9e0e-51a0b2c2c66e},
 group_id = {d9389c6c-8ab5-3b8b-86ed-33db09ca0198},
 last_modified = {2019-03-23T00:05:35.143Z},
 tags = {CA},
 read = {false},
 starred = {false},
 authored = {false},
 confirmed = {true},
 hidden = {false},
 citation_key = {Steelman2018},
 notes = {LB},
 private_publication = {false},
 abstract = {1 Purpose Currently only one‐third of patients treated for depression enjoy complete remission of their negative symptoms. This paper explores ketamine research as it applies to understanding and treating mood illnesses. 2 Conclusions Ketamine's rapid antidepressant effect implicates downstream signal transduction involving the spontaneous transmissions associated with ketamine's action at the NMDA receptor. 3 Practice Implications Better understanding of brain neuropathophysiology offers hope for symptom relief to those living with affective illness refractory to currently available medical management.},
 bibtype = {article},
 author = {Steelman, Brittany Carnley},
 journal = {Perspectives in Psychiatric Care}
}

{"_id":"D8sKuJZgYjdJ7ydR8","bibbaseid":"steelman-apivotfromsynapticmonoamineprocessestofurtherdownstreamprocessestheimpactofketamineresearch-2018","downloads":0,"creationDate":"2018-11-08T14:42:26.643Z","title":"A pivot from synaptic monoamine processes to further downstream processes: The impact of ketamine research","author_short":["Steelman, B., C."],"year":2018,"bibtype":"article","biburl":null,"bibdata":{"title":"A pivot from synaptic monoamine processes to further downstream processes: The impact of ketamine research","type":"article","year":"2018","identifiers":"[object Object]","pages":"1-4","websites":"http://doi.wiley.com/10.1111/ppc.12317","month":"7","publisher":"Wiley/Blackwell (10.1111)","day":"24","id":"17a97430-5709-35dd-b71d-1df9c0f10500","created":"2018-11-07T20:29:07.373Z","accessed":"2018-07-29","file_attached":false,"profile_id":"078d13e5-632a-3ebf-9e0e-51a0b2c2c66e","group_id":"d9389c6c-8ab5-3b8b-86ed-33db09ca0198","last_modified":"2019-03-23T00:05:35.143Z","tags":"CA","read":false,"starred":false,"authored":false,"confirmed":"true","hidden":false,"citation_key":"Steelman2018","notes":"LB","private_publication":false,"abstract":"1 Purpose Currently only one‐third of patients treated for depression enjoy complete remission of their negative symptoms. This paper explores ketamine research as it applies to understanding and treating mood illnesses. 2 Conclusions Ketamine's rapid antidepressant effect implicates downstream signal transduction involving the spontaneous transmissions associated with ketamine's action at the NMDA receptor. 3 Practice Implications Better understanding of brain neuropathophysiology offers hope for symptom relief to those living with affective illness refractory to currently available medical management.","bibtype":"article","author":"Steelman, Brittany Carnley","journal":"Perspectives in Psychiatric Care","bibtex":"@article{\n title = {A pivot from synaptic monoamine processes to further downstream processes: The impact of ketamine research},\n type = {article},\n year = {2018},\n identifiers = {[object Object]},\n pages = {1-4},\n websites = {http://doi.wiley.com/10.1111/ppc.12317},\n month = {7},\n publisher = {Wiley/Blackwell (10.1111)},\n day = {24},\n id = {17a97430-5709-35dd-b71d-1df9c0f10500},\n created = {2018-11-07T20:29:07.373Z},\n accessed = {2018-07-29},\n file_attached = {false},\n profile_id = {078d13e5-632a-3ebf-9e0e-51a0b2c2c66e},\n group_id = {d9389c6c-8ab5-3b8b-86ed-33db09ca0198},\n last_modified = {2019-03-23T00:05:35.143Z},\n tags = {CA},\n read = {false},\n starred = {false},\n authored = {false},\n confirmed = {true},\n hidden = {false},\n citation_key = {Steelman2018},\n notes = {LB},\n private_publication = {false},\n abstract = {1 Purpose Currently only one‐third of patients treated for depression enjoy complete remission of their negative symptoms. This paper explores ketamine research as it applies to understanding and treating mood illnesses. 2 Conclusions Ketamine's rapid antidepressant effect implicates downstream signal transduction involving the spontaneous transmissions associated with ketamine's action at the NMDA receptor. 3 Practice Implications Better understanding of brain neuropathophysiology offers hope for symptom relief to those living with affective illness refractory to currently available medical management.},\n bibtype = {article},\n author = {Steelman, Brittany Carnley},\n journal = {Perspectives in Psychiatric Care}\n}","author_short":["Steelman, B., C."],"urls":{"Website":"http://doi.wiley.com/10.1111/ppc.12317"},"bibbaseid":"steelman-apivotfromsynapticmonoamineprocessestofurtherdownstreamprocessestheimpactofketamineresearch-2018","role":"author","downloads":0},"search_terms":["pivot","synaptic","monoamine","processes","further","downstream","processes","impact","ketamine","research","steelman"],"keywords":[],"authorIDs":[]}